Literature DB >> 3907687

Fifteen-year follow-up of all patients in a study of post-operative chemotherapy for bronchial carcinoma.

D J Girling, H Stott, R J Stephens, W Fox.   

Abstract

The 15-year findings are presented of a double-blind, randomised study planned in 1964 in which cytotoxic chemotherapy with either busulphan or cyclophosphamide prescribed to be given daily for 2 years as an adjuvant to surgery was compared with placebo in the treatment of 726 patients with carcinoma of the bronchus. The two cytotoxic agents administered in this way did not influence survival. At 15y, 8% of the 243 patients allocated busulphan, 9% of the 234 cyclophosphamide, and 10% of the 249 placebo were alive, these being 10% of the patients who had had epidermoid cancers, 12% large-cell, 5% small-cell, 5% adenocarcinomas, and 8% other histological types. The study provides data on long-term results in a large group of patients who were, in effect, treated by surgery alone. Survival was significantly shorter in patients with histological involvement of the resected intrathoracic nodes (log-rank test P much less than 0.001). A finding of particular interest is that the histological type of the tumour did not influence survival in the 390 patients whose nodes were not involved, although, as expected, it did in the 336 whose nodes were involved, the 226 with epidermoid cancers surviving longer than the 57 with small cell carcinoma, the 31 with adenocarcinoma and all 110 with non-epidermoid carcinomas (P much less than 0.001 in each comparison).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907687      PMCID: PMC1977284          DOI: 10.1038/bjc.1985.271

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  The solitary pulmonary nodule. Ten-year follow-up of veterans administration-armed forces cooperative study.

Authors:  G A Higgins; T W Shields; R J Keehn
Journal:  Arch Surg       Date:  1975-05

2.  SURGICAL TREATMENT OF CARCINOMA OF THE BRONCHUS.

Authors:  J R BELCHER; R ANDERSON
Journal:  Br Med J       Date:  1965-04-10

3.  Use of chemotherapy as an adjuvant to surgery for bronchogenic carcinoma.

Authors:  G A Higgins
Journal:  Cancer       Date:  1972-11       Impact factor: 6.860

Review 4.  An assessment of massive-dose chemotherapy of malignant disease.

Authors:  D E Bergsagel
Journal:  Can Med Assoc J       Date:  1971-01-09       Impact factor: 8.262

5.  Remission rates, survival, and prognostic factors in combination chemotherapy for bronchogenic carcinoma.

Authors:  P Alberto
Journal:  Cancer Chemother Rep 3       Date:  1973-03

6.  Importance of dose schedules in adjuvant chemotherapy.

Authors:  K Karrar
Journal:  Cancer Chemother Rep       Date:  1972-02

7.  Survival in lung cancer; effectiveness of surgery.

Authors:  J L Pool
Journal:  N Y State J Med       Date:  1971-09-01

8.  Prognostic factors in lung cancer. Surgical aspects.

Authors:  G A Higgins; R Lawton; A Heilbrunn; R J Keehn
Journal:  Ann Thorac Surg       Date:  1969-05       Impact factor: 4.330

9.  Alkylating agents in bronchogenic carcinoma.

Authors:  R A Green; E Humphrey; H Close; M E Patno
Journal:  Am J Med       Date:  1969-04       Impact factor: 4.965

10.  Bronchogenic carcinoma. Factors in survival.

Authors:  G A Higgins; G W Beebe
Journal:  Arch Surg       Date:  1967-04
View more
  3 in total

Review 1.  Neoadjuvant chemotherapy in stage IIIa non-small cell lung cancer.

Authors:  R Milroy; F Macbeth
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

2.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.

Authors: 
Journal:  BMJ       Date:  1995-10-07

3.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.